NCT00228540已完成3 期
An 8 Week, Open-Label Study to Characterize the Response to Modafinil (85 mg Film Coated Tablet) Treatment at Dosages Up to 425 mg/Day in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD) (With an Open Ended Extension Period)
Cephalon74 个研究点 分布在 1 个国家开始时间: 2005年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 74
研究概览
简要总结
An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients are included in the study if all of the following criteria are met:
- •Written informed consent/assent is obtained.
- •The patient is a boy or girl 6 through 17 years of age (inclusive) at the screening visit, and both the patient and parent/legal guardian are English-speaking.
- •The patient has a previous diagnosis of ADHD and is currently receiving medication for the treatment of ADHD.
- •The patient, or the patient's parent/legal guardian, is dissatified (VAS score <50) with current ADHD medication (medication and reason for dissatisfaction documented).
- •The patient is in good health as determined by a medical or psychiatric history, screening physical examination, and clinical laboratory evaluations.
- •Girls who are postmenarche or sexually active, must have a negative urine pregnancy test prior to the baseline visit, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include the following: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implant, or injected) in conjunction with a barrier method; intrauterine device (IUD); and abstinence.
- •The patient's parent/legal guardian must be willing and able to comply with study procedures and restrictions.
排除标准
- •Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- •The patient has any current psychiatric comorbidity, including but not limited to depression or other mood disorder, or pervasive mental disorder, that requires pharmacotherapy.
- •The patient is satisfied with current ADHD medication and has no side effects.
- •The patient is using other prescription medications for ADHD with psychoactive properties (eg, amphetamine, dextroamphetamine, methylphenidate, pemoline, atomoxetine) after the baseline visit.
- •The patient has used monoamine oxidase (MAO) inhibitors within 1 week before the baseline visit.
- •The patient has used an investigational drug within 1 month before the screening visit.
- •The patient has a known clinically significant drug sensitivity to modafinil or any of its inactive ingredients.
- •The patient is pregnant or lactating. (Any patients becoming pregnant during the study will be withdrawn from study).
研究者
研究点 (74)
Loading locations...
相似试验
已完成
3 期
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeExcessive Daytime SleepinessNarcolepsyObstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)NCT00228566Cephalon247
已完成
3 期
Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil TreatmentAttention Deficit Hyperactivity DisorderNCT00343811Cephalon120
已完成
不适用
Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With SchizophreniaSchizophreniaNCT00546403Veterans Medical Research Foundation26
已完成
3 期
Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHDAttention Deficit/Hyperactivity DisorderADHDNCT00214981Cephalon
终止
3 期
Modafinil in Opioid Induced SedationPainCancerNCT00267332Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins90